What the Radiation Oncology Community is Saying About Adaptive Radiotherapy (ART): Insights from SeeTreat's LinkedIn Polls

Offline ART Remains the Go-To Approach

Although online ART continues to generate buzz, most respondents indicated they are still using offline ART—33% with treatment planning or QA software, and 28% with other offline tools. Online ART adoption came in at 22% using a standard Linac and only 17% using an MR Linac. This reflects ongoing concerns about workflow integration, cost, and the complexity of online adaptive solutions.

Head & Neck is the Leading Application

When asked which anatomical site clinicians are most eager to apply ART to, head and neck led overwhelmingly (64%), followed by prostate (25%), lung (7%), and breast (4%). These responses echo conversations at ESTRO 2025, where clinicians pointed to the precision needs of anatomically complex, high-motion regions such as head and neck.

Strong Interest in Daily Dose Accumulation

In our final poll, we asked: If there were an efficient, accurate way to perform daily dose accumulation, would you use it? Every respondent said yes — underscoring a universal interest in more advanced, yet practical, ART tools.

What's Next?

These poll results echo what institutions report globally: while the clinical rationale for ART is clear, the operational burden is high. For example, traditional offline adaptive workflows can take up to 5 days to complete due to the manual effort required across multiple software platforms and team members. There's a growing call for intelligent, integrated solutions that reduce this burden and enable faster, evidence-based replan decisions—ideally in minutes, not days.

ART.1 from SeeTreat is Closing the Gap

ART.1 is purpose-built software for Adaptive Radiotherapy that automates the most resource-intensive components of adaptive workflows. ART.1 enables a more streamlined, scalable approach to broadening access to and accelerating adaptive workflows. To learn more, ask for a demo.

Thanks to everyone who joined the conversation. If you haven't yet, follow SeeTreat on LinkedIn. We're just getting started!

Note: These results are based on a limited LinkedIn sample of 62 participants and are intended to provide a snapshot of current perspectives, not a comprehensive industry survey. Still, they offer a valuable pulse on where interest and challenges lie as ART continues to evolve.